Recessive Dystrophic Epidermolysis Bullosa
Dermatology·MeSH: Epidermolysis Bullosa Dystrophica
Prevalence
0.5 / 100K
8 drugs in development·6 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| zevaskyn | ABEONA THERAPEUTICS INC. (ABEO) |
Phase 3(3)
BLA Filed(2)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| fcx-007 | Fibrocell Science, Inc. (FCSC) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| qrx004 | Quoin Pharmaceuticals, Ltd. (QNRX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Recessive Dystrophic Epidermolysis Bullosa?
BioSniper tracks 8 drugs in development for Recessive Dystrophic Epidermolysis Bullosa across 6 companies.
How many clinical trials target Recessive Dystrophic Epidermolysis Bullosa?
There are 3 clinical trials targeting Recessive Dystrophic Epidermolysis Bullosa tracked by BioSniper.
What is the prevalence of Recessive Dystrophic Epidermolysis Bullosa?
The estimated prevalence of Recessive Dystrophic Epidermolysis Bullosa is approximately 0.5 per 100,000 population.
Deep-dive into Recessive Dystrophic Epidermolysis Bullosa
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis